ExpreS2ion
H├╕rsholm · Founded 2010
About ExpreS2ion
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.
Company Facts
- Founded: 2010
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $58.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2025)
- Ticker: sto:EXPRS2
- Website: http://expres2ionbio.com/
- Phone: +45 2222 1019
Industries & Categories
Biopharma, Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/expres2ion-5380 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.